108: Menopause, Ketones, and Metabolism: A Strategy Explained

Bikman presents this as the traditional, well-established method to raise ketones. He emphasizes that when insulin is chronically elevated (from high-carb diets), ketogenesis is suppressed. By reducing dietary carbohydrate, insulin falls, and the body shifts to fat burning, naturally producing ketones. He acknowledges the strictness but believes it's a powerful tool for metabolic health, especially when estradiol is declining.

Bikman describes three categories: ketone electrolytes (BHB bound to sodium, potassium, etc.) — affordable, common, moderate ketone boost; ketone esters (precursor that liver converts) — more potent, rapid, but bad taste; free acid BHB — straight bioidentical ketone, efficient absorption. He personally uses them sometimes, acknowledging the practicality despite his preference for dietary change. He sees a clear role for exogenous ketones in menopause to complement or substitute for endogenous production.

Bikman explains that the shorter the fat, the more it is obligated to be burned rather than stored. MCTs are absorbed quickly and shunted to the liver, where they are preferentially oxidized. This high rate of fat oxidation drives ketogenesis. He presents MCTs as a practical tool to raise ketones without full dietary restriction, complementing both ketogenic diets and exogenous ketones.

Bikman highlights his lab's finding that insulin forces fat mitochondria to be tightly coupled, limiting energy waste. He then notes that ketones do the opposite — they promote uncoupling. Therefore, a woman going through menopause, who has lost estradiol's protective effects on fat distribution, can benefit from simultaneously lowering insulin (via diet) and raising ketones. This dual strategy allows mitochondria to 'burn faster and hotter,' potentially mitigating the metabolic consequences of menopause. He frames it as a practical takeaway from his research.

Bikman details how estradiol normally upregulates glucose transporters and glycolytic enzymes in the brain, supports neurotrophic factors, and modulates neurotransmitters. Menopause compromises these processes, leading to cognitive symptoms. He then explains that BHB can step in as an alternative fuel, and research shows it enhances neuroplasticity and reduces neuroinflammation. This makes ketones a logical intervention for brain health during menopause.

Bikman's team studied isolated fat cells, rodent fat tissue, and human fat biopsies. When ketones were elevated, mitochondrial oxygen consumption more than doubled — nearly tripling in humans — yet ATP production did not rise proportionally. This uncoupling means mitochondria burn fat and glucose to release heat rather than store energy, effectively increasing metabolic rate. Gene expression analysis revealed upregulation of PGC1α (mitochondrial biogenesis) and UCP1 (the key uncoupling protein). Bikman contrasts this with muscle, where BHB increases coupling for efficient ATP production. He also notes that insulin suppresses uncoupling, so lowering insulin via diet removes a brake, allowing ketones to further drive fat burning. This dual mechanism could be especially valuable during menopause, when estradiol's protective effects on fat distribution and cell size are lost.

Bikman cites a recent study where a ketone electrolyte supplement reduced circulating branched-chain amino acids (BCAAs), which are released during muscle breakdown. This suggests decreased proteolysis. His own lab then showed that BHB treatment in isolated muscle cells and whole animals improved mitochondrial respiration, resulting in tighter coupling (more ATP per nutrient burned) and increased mitochondrial fusion. Fusion is associated with healthier, more efficient mitochondria. Together, these effects would help maintain muscle protein content and energy production, countering the catabolic shift of menopause.

Bikman's team exposed cells to uric acid, which triggered a significant increase in pro-inflammatory cytokines. Co-incubation with BHB completely blocked this response. Additionally, BHB preserved mitochondrial function and insulin signaling despite the inflammatory challenge. This suggests BHB can protect against inflammation-driven metabolic damage. Since menopause increases inflammation and uric acid levels can rise with metabolic dysfunction, BHB may offer a dual protective role.

Bikman notes that while the liver can convert some L-BHB to D-BHB, early research hints that L-BHB may act as a signaling molecule with distinct effects, especially in the brain. Given that the brain is highly susceptible to estradiol loss during menopause, L-BHB could prove more than a passive byproduct. This is speculative but aligns with the broader theme of ketones as pleiotropic agents.

Bikman walks through five systems: brain (impaired glucose uptake, neuroinflammation), muscle (increased proteolysis, reduced anabolic signaling), mitochondria (reduced biogenesis, increased oxidative stress), fat tissue (shift to visceral fat, larger adipocytes), and inflammation (loss of anti-inflammatory regulation). In each case, he explains how BHB can step in — crossing the blood-brain barrier to provide fuel and enhance neuroplasticity, reducing muscle protein breakdown and improving mitochondrial coupling, stimulating mitochondrial biogenesis and antioxidant defenses, driving fat tissue uncoupling to waste energy as heat, and inhibiting the NLRP3 inflammasome. He concludes that raising ketones, whether through diet or exogenous supplements, may help women 'weather the metabolic storm of menopause a little more readily.'